The multiple studies of HORMAD1 function in tumors suggest a mixture of genomic protection and disruption, depending on the stage and type of cancer or additional changes in DNA repair pathways (BRCA1/2 mutation, ATM/ATR loss, and so on). The gene discussed is ATR; the disease is cancer.